Associate Professor

Dr Manzoor was Born at Trehgam Kupwara Kashmir. He completed his M Sc in Life Sciences (Zoology). He qualified JRF-NET and joined Ph. D in Immunology at IMTECH-CSIR-JNU. In 2009 he topped the Asstt. Prof List by JKPSC & in 2011 he was nominated as Nodal Officer for Kashmir University Satellite Campus at Kupwara. He got selected as Asstt. Prof in Deptt of Bioresources, KU in 2012 . He worked in SATCAS Stroke Research Chair with Prof Raid at MU KSA from 2013-2015. He has wrote seven international books with reputed international Publishers like Elsivier USA, Nova Science Publishers USA and Academic Press USA. He has published many research articles in the Journals of internal repute which include, Cellular Oncology, Breast Cancer, Current drug targets,  Current Pharmaceutical Biotechnology, Future Oncology, Microbiological Research, Journal of Biomedical Nanotechnology, Current Cancer Drug Targets, Plos One, Expert Opinion in Therapeutic Targets, Frontiers in Neurosciences, Stroke, Advances in Neuroimmune Biology etc. He has presented research papers and delivered talks in various international Scientific conferences in the countries like USA, UK, China, Bahrain, UAE, Scotland, Kuwait & Sri lanka. His Research interests include, Immunobiology of Cancer, Immunology of Tubersulosis and Immunology of Stroke. He is member of many scientific organizations and societies like American Association of Cancer Research, Fellow of Royal British Society, International Immunology Association, Indian Cancer Society, Indian Immunology Society, Indian National Science Association, IMMUNOCON etc. Dr Manzoor was awarded Teachers Associate Research Excellence Fellowship (TARE) by DST Govt of India. He has been awarded Summer Research Fellowship Programme (SRFP-2019) by Indian Academy of Sciences and National Science Academy. He was awarded a research project on combination therapy in breast cancer by Jammu Kashmir Science Technology and Innovation council, Govt of J&K. Dr Manzoor has developed Massive Open Online Course (MOOCs) in Immunology course and Endocrinology course for UG students sanctioned by UGC-Consortium for Educational Communication (CEC) SWAYAM Ministry of HRD Govt of India. He has research and teaching experience of 15 years. He currently teaches Cancer Biology, and Immunology at the Department of Bioresources, School of Biological Sciences, University of Kashmir. He is presently heading the Department of Bioresources, University of Kashmir.

Faculty Details

  • Citations 3230
  • HIndex 31
  • i10 Index 101
  • Mobile 9622901319
  • Email drmanzoor@kashmiruniversity.ac.in
  • Administrative position Held Head, Department of Bioresources, School of Biological Sciences
  • Resume View



Research Papers Published

  • "Inflammatory Mechanisms as Potential Therapeutic Targets in Stroke" Advances in Neuroimmune Biology, 5(1): 199 -216 {ISSN: 1878-9498} Impact Factor=
  • "Effect of Supine Versus Semi-Fowler’s Position on Hemodynamic stability of patients with Head injury" World Journal of Pharmaceutical Research, 4(4): 121 -130 {ISSN: 2277-7105} Impact Factor=
  • "123I-FP-CIT SPECT imaging in early diagnosis of dementia in patients with and without a vascular component" Frontiers in System Neurosciences, 9(99): 1 -11 {ISSN: 1662-5137} Impact Factor=
  • "Immunomodulation of Inflammatory Markers in Activated Macrophages by Leaf Extracts of Gingko Biloba" Advances in Neuroimmune Biology, 5(5): 127 -139 {ISSN: 1878-9498} Impact Factor=
  • "TNF Receptor Modulation by Gentiana Extracts Acts as Neuroprotective Mechanism in Stroke by Enhancing Cellular Survival." Stroke, 45(12): e259 -298 {ISSN: 1524-4628} Impact Factor=
  • "Immunomodulation of Inflammatory Markers in Activated Macrophages by Leaf Extracts of Gingko Biloba" Advances in Neuroimmune Biology, 6(1): 9 -17 {ISSN: 1878-9498} Impact Factor=
  • "BAD a Proapoptotic Protein Escapes ERK RSK Phosphorylation in Deguelin and siRNA Treated HeLa Cells" Plos One, 11(1): Pub Med ID. PMC4706341 {ISSN: 19326203} Impact Factor= 3.3
  • "Impact of co-signaling on the survival of intracellular pathogens in macrophages" International Journal of Advance Research in Science and Engineering, 7(4): 3166 -3183 {ISSN: 2319-8354} Impact Factor=
  • "Double-Crosser of the Immune System: Macrophages in tumor progression and metastasis" Current Immunological Reviews, 15(2): DOI No. 10.2174/1573395515666190611122 {ISSN: 1875-631X} Impact Factor= 0.657
  • "Recent advances in metabolites from medicinal plants in cancer prevention and treatment" Current Immunological, 15(2): DOI No. 10.2174/1573395515666191102094 {ISSN: 1875-631X} Impact Factor= 0.657
  • "Nanobodies: the magic bullets in therapeutics, drug delivery and diagnostics" Human Antibodies, 21(1): DOI No. 10.3233/HAB-190390 {ISSN: 1875-869X} Impact Factor= 0.456
  • "Recent Advances in Chemotherapeutic Implications of Deguelin, A Plant Derived Retinoid" The Natural Products Journal, 11(2): DOI No. 10.2174/2210315510666200128125 {ISSN: 2210-3163} Impact Factor= 0.856
  • "Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer" Current Cancer Drug Targets, 20(8): DOI No. 10.2174/1570163817666200518081 {ISSN: 1873-5576} Impact Factor= 3.324
  • "Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis" Current Pharmaceutical Biotechnology, 22(4): DOI No. 10.2174/1389201021666200628021 {ISSN: 1873-4316} Impact Factor= 2.354
  • "Rising trends of Cancers in Kashmir valley: Distribution Pattern, Incidence and Causes" Journal of Oncology Research and Treatment, 5(2): 150 -163 Impact Factor= 078
  • "Novel Strategies to Combat the Emerging Drug Resistance in Human Pathogenic Microbes" Current Drug Targets, 22(17): DOI No. 10.2174/1389450121666201228123 {ISSN: 1873-5592} Impact Factor= 2.868
  • "Tumor microenvironment promotes breast cancer chemoresistance" Cancer Chemotherapy and Pharmacology, 87(2): DOI No. 10.1007/s00280-020-04222-w {ISSN: 1432-0843} Impact Factor= 2.967
  • "Glucose - The X factor for the survival of human fungal pathogens and disease progression in the host" Microbial Research, 247(6): DOI No. 10.1016/j.micres.2021.126725 {ISSN: 2036-7481} Impact Factor= 3.978
  • "Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives" Breast Cancer, 28(3): DOI No. 10.1007/s12282-021-01231-2 {ISSN: 1880-4233} Impact Factor= 2.695
  • "Recent Advances in Chemotherapeutic Implications of Deguelin: A Plant-Derived Retinoid" The Natural Products Journal, 11(2): DOI No. 10.2174/2210315510666200128125 {ISSN: 2210-3163} Impact Factor=
  • "Comparative Study on Phytochemical Profile and Antioxidant Activity of an Epiphyte, Viscum album L. (White Berry Mistletoe), Derived from Different Host Trees" Plants, 10(6): DOI No. 10.3390/plants10061191 {ISSN: 2223-7747} Impact Factor= 3.935
  • "Glucose - The X factor for the survival of human fungal pathogens and disease progression in the host" Microbiological Research, 247(6): DOI No. 10.1016/j.micres.2021.126725 {ISSN: 0944-5013} Impact Factor= 5.415
  • "Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives" Breast Cancer, 28(5): DOI No. 10.1007/s12282-021-01231-2 {ISSN: 1880-4233} Impact Factor= 4.234
  • "Development of New Therapeutics to Meet the Current Challenge of Drug Resistant Tuberculosis" Current Pharmaceutical Biotechnology, 22(4): DOI No. 10.2174/1389201021666200628021 {ISSN: 1873-4316} Impact Factor= 2.987
  • "Tumor microenvironment promotes breast cancer chemoresistance" Cancer Chemotherapy and Pharmacology, 87(2): DOI No. 10.1007/s00280-020-04222-w {ISSN: 1432-0843} Impact Factor= 3.333
  • "The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities" Cellular Oncology, 44(5): DOI No. 10.1007/s13402-021-00634-9 {ISSN: 22113428} Impact Factor= 6.730
  • "An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer" Future Oncology, 17(31): DOI No. 10.2217/fon-2021-0172 {ISSN: 1744-8301} Impact Factor= 3.404
  • "Strategies employed to evade the host immune response and the mechanism of drug resistance in Mycobacterium tuberculosis: In search of finding new targets" Current Pharmaceutical Biotechnology, 22(17): DOI No. 10.2174/1389201023666211222164 {ISSN: 1873-4316} Impact Factor= 2.987
  • "Nano-Drug Delivery Systems: Possible End to the Rising Threats of Tuberculosis" Journal of Biomedical Nanotechnology, 17(12): DOI No. 10.1166/jbn.2021.3201 {ISSN: 1550-7041} Impact Factor= 4.483
  • "In vitro and in silico evaluation of antimicrobial properties of Delphinium cashmerianum L., a medicinal herb growing in Kashmir, India" Journal of Ethnopharmacology, 291(6): DOI No. 10.1016/j.jep.2022.115046 {ISSN: 0378-8741} Impact Factor= 4.360
  • "Expression pattern and prognostic significance of baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) in breast cancer: A comprehensive analysis" Advances in Cancer Biology - Metastasis, 4(7): DOI No. 10.1016/j.adcanc.2022.100037 {ISSN: 2667-3940} Impact Factor=
  • "Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications" Seminars in Cancer Biology, 80(3): DOI No. 10.1016/j.semcancer.2022.03.00 {ISSN: 1044-579X} Impact Factor= 15.707
  • "Metformin treatment ameliorates endocrine-metabolic disturbances in letrozole-induced PCOS mice model by modulating adiponectin status" Obesity Medicine, 31(5): DOI No. 10.1016/j.obmed.2022.100392 {ISSN: 2451-8476} Impact Factor= 1.5
  • "Chemokines in triple- negative breast cancer heterogeneity: New challenges for clinical implications" Seminars in Cancer Biology, 84(3): DOI No. 1 {ISSN: 1044-579X} Impact Factor= 17.012
  • "Adapalene and doxorubicin synergistically promote apoptosis of TNBC Cells by hyperactivation of the ERK1/2 pathway through ROS induction" Frontiers in Oncology, 12(6): DOI No. 10.338 {ISSN: 2234-943X} Impact Factor= 6.244
  • "Adapalene inhibits the growth of triple-negative breast cancer cells by S-phase arrest and potentiates the antitumor efficacy of GDC- 0941" Frontiers in Pharmacology, 13(7): DOI No. 10.3389/ {ISSN: 1663-9812} Impact Factor= 5.988
  • "Expression patterns and therapeutic implications of CDK4 across multiple carcinomas: a molecular docking and MD simulation study" Medical Oncology, 39(10): DOI No. 10.1007/s12032-022-01779-9 {ISSN: 1559131X} Impact Factor= 3.738
  • "Expression Pattern and Prognostic Significance of Chemokines in Breast cancer: An Integrated Bioinformatics Analysis" Clinical Breast Cancer, 22(5): DOI No. 10.1016/j. clbc.2022.04.008 {ISSN: 1526-8209} Impact Factor= 3.225
  • "Cryptolepine Targets TOP2A and Inhibits Tumor Cell Proliferation in Breast Cancer Cells - An in vitro and in silico Study" Anti-Cancer Agents in Medicinal Chemistry, 22(3): DOI No. 10.2174/1871520622666220419135 {ISSN: 18755992} Impact Factor= 2.680
  • "Expression Pattern and Prognostic significance of CDKs in Breast Cancer: An Integrated Bioinformatic Study." Cancer Biomarkers, 34(3): DOI No. 10.3233/CBM-210186 {ISSN: 505-519} Impact Factor= 4.333
  • "Cyclin-Dependent Kinases in Breast Cancer: Expression Pattern and Therapeutic Implications" Medical Oncology, 34(6): DOI No. 10.1007/s12032-022-01731-x {ISSN: 1559131X} Impact Factor= 3.738
  • "antimicrobial properties of Delphinium cashmerianum L., a medicinal herb growing in Kashmir, India." Journal of Ethnopharmacology, 297(6): DOI No. 10.1016/j.jep.2022.115046 {ISSN: 0378-8741} Impact Factor= 5.107
  • "Natural therapeutics in aid of treating Alzheimer’s disease (AD): A green gateway towards ending the quest for treating neurological disorders" Frontiers in Neuroscience, 16(6): DOI No. 10.3389/fnins.2022.884345 {ISSN: 1662-453X} Impact Factor= 4.501
  • "Quinidine Drug Resistance transporter Knockout Candida cells modulate glucose transporter expression and accumulate metabolites leading to enhanced azole drug resistance" Fungal Genetics and Biology, 161(7): DOI No. 10.1016/j.fgb. {ISSN: 10871845} Impact Factor= 3.883
  • "Targeting Cyclin-dependent kinase 1 (CDK1) in Cancer: Molecular Docking and Dynamic Simulations of potential CDK1 Inhibitors" Medical Oncology, 39(4): DOI No. 10.1007/s {ISSN: 1559131X} Impact Factor= 3.738
  • "Strategies employed to evade the host immune response and the mechanism of drug resistance in Mycobacterium tuberculosis: In search of finding new targets" Current Pharmaceutical Biotechnology, 23(1): DOI No. 10.2174/1389201023666211222164 {ISSN: 1873-4316} Impact Factor= 2.840
  • "Evaluation of the In Vitro Antimicrobial Activities of Delphinium roylei: An Insight from Molecular Docking and MD-Simulation Studies" Medicinal Chemistry, 18(4): DOI No. 10.2174/1573406418666220429093 {ISSN: 1875-6638} Impact Factor= 2.329
  • "Manipulation and exploitation of host immune system by pathogenic Mycobacterium tuberculosis for its advantage" Future Microbiology, 17(8): DOI No. 10.2217/fmb-20 {ISSN: 1746-0913} Impact Factor= 3.553
  • "Natural products and their semi-synthetic derivatives against antimicrobial-resistant human pathogenic bacteria and fungi" Saudi Journal of Biological Sciences, 29(9): DOI No. 10.1016/j.sjbs {ISSN: 1319-562X} Impact Factor= 4.052
  • "Molecular docking analysis and evaluation of the antimicrobial properties of the constituents of Geranium wallichianum D. Don ex Sweet from Kashmir Himalaya" Scientific Reports (Springer-Nature), 12(7): DOI No. 10.1038/s41598-022-16102-9 {ISSN: 2045-2322} Impact Factor= 4.996
  • "Metabolite fingerprinting of phytoconstituents from Fritillaria cirrhosa D. Don and molecular docking analysis of bioactive peonidin with microbial drug target proteins." Scientific Reports (Nature Springer), 12(5): DOI No. 10.1038/s 4159 {ISSN: 245-2322} Impact Factor= 4.996
  • "Expression pattern and prognostic significance of baculoviral inhibitor of apoptosis repeat- containing 5 (BIRC5) in breast cancer: A comprehensive analysis." Advances in Cancer Biology-Metastasis, 4(3): DOI No. 10.1016/j. adc {ISSN: 2667-3940} Impact Factor= 0.0
  • "Metformin treatment ameliorates endocrine metabolic disturbances in the letrozole-induced PCOS mice model by modulating adiponectin Status" Obesity Medicine, 31(5): DOI No. 10.1016/j.obme {ISSN: 24518476} Impact Factor= 0.00
  • "A Novel Prognostic Biomarker with Potential of High Diagnostic Accuracy in Pulmonary Tuberculosis: An in silico Study" International Journal of Pharmaceutical Investigation, 12(2): DOI No. 10.5530/ijpi.2 {ISSN: 2230-9713} Impact Factor= 0.00
  • "Chlorogenic acid restores ovarian functions in mice with letrozole-induced polycystic ovarian syndrome via modulation of adiponectin receptor" Biomedicines, 11(3): DOI No. 10.3390/biomedicines11030900 {ISSN: 2227-9059} Impact Factor= 4.757
  • "Ginger extract ameliorates endocrine-metabolic disturbances in letrozoleinduced PCOS mice model by altering androgen-adiponectin status" Obesity Medicine, 39(3): DOI No. 10.1016/j.obmed.2023.100485 {ISSN: 2451-8476} Impact Factor= 1.323
  • "Synthesis and Biological Evaluation of Novel Uracil Derivatives as Thymidylate Synthase Inhibitors" Applied Biochemistry and Biotechnology, 195(2): DOI No. 10.1007/s12010-023-04367-3 {ISSN: 2732289} Impact Factor= 3.094
  • "Immunomodulatory efficacy of Cousinia thomsonii C.B. Clarke in ameliorating inflammatory cascade expressions" Journal of Ethnopharmacology, 300(1): DOI No. 10.1016/j.jep.2022.115727 {ISSN: 1872-7573} Impact Factor= 5.195
  • "A systematic review on the safety and eìcacy of COVID-19 vaccines approved in Saudi Arabia" Vaccines, 11(2): DOI No. 10.3390/vaccines11020281 {ISSN: 2076-393X} Impact Factor= 4.961
  • "Identiêcation and analysis of dysregulated fatty acid metabolism genes in breast cancer subtypes" Medical Oncology, 39(10): DOI No. 10.1007/s12032-022-01861-2 {ISSN: 1559131X} Impact Factor= 3.738
  • "Molecular Prediction and Correlation of the Structure and Function of Universal Stress Protein A (UspA) from Salmonella Typhimurium" Biochemical Genetics, 62(2): DOI No. 10.1007/s10528-024-10699-4 {ISSN: 1573-4927} Impact Factor= 2.4
  • "Transcription Factors-Golden Keys to Modulate the Plant Metabolism to Develop Salinity Tolerance" Plant Stress, 11(3): DOI No. 10.1016/j.stress.2024.100409 {ISSN: 2667-064X} Impact Factor= 5.4
  • "Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology" Heliyon, 10(7): DOI No. 10.1016/j.heliyon.2024.e24670 {ISSN: 2405-8440} Impact Factor= 4.2
  • "Targeting p53 misfolding conundrum by stabilizing agents and their analogs in breast cancer therapy: a comprehensive computational analysis" Frontiers in Pharmacology, 10(14): DOI No. 10.3389/fphar.2023.1333447 {ISSN: 1663-9812} Impact Factor= 5.828
  • "Deciphering the chemical constituents and antimicrobial activity of Prangos pabularia Lindl. using LC-MS/MS in combination with experimental evaluation and computational studies" Natural Product Chemistry, 38(2): DOI No. 10.1080/14786419.2023.2300394 {ISSN: 1478-6427} Impact Factor= 2.488
  • "Clinicopathological Significance and Expression Pattern of Bcl2 in Breast Cancer: A Comprehensive in silico and in vitro Study" Saudi Journal of Biological Sciences, 31(2): DOI No. 10.1016/j.sjbs.2023.103916 {ISSN: 1319-562X} Impact Factor= 4.465
  • "Network pharmacology and experimental validation for deciphering the action mechanism of Fritillaria cirrhosa D. Don constituents in suppressing breast carcinoma" Journal of Biomolecular Structure and Dynamics, 41(20): DOI No. 10.1080/07391102.2023.2274966 {ISSN: 1538-0254} Impact Factor= 5.678
  • "Administration of metformin ameliorates endocrine abnormalities associated with mouse model of PCOS by increasing Cyp19a1 expression" Comparative Clinical Pathology, 33(4): DOI No. 10.1007/s00580-023-03534-6 {ISSN: 1618-565X} Impact Factor= 0.97
  • "Decoding the molecular mechanism of stypoldione against breast cancer through network pharmacology and experimental validation" Saudi Journal of Biological Sciences, 30(12): DOI No. 10.1016/j.sjbs.2023.103848 {ISSN: 1319-562X} Impact Factor= 4.465
  • "Targeting Breast Cancer Stem Cells through Retinoids: A New Hope for Treatment" Critical Reviews in Oncology/Hematology, 192(12): DOI No. 10.1016/j.critrevonc.2023.1041 {ISSN: 1040-8428} Impact Factor= 6.256
  • "Network pharmacology combined with molecular docking and in vitro verification reveals the therapeutic potential of Delphinium roylei munz constituents on breast carcinoma" Frontiers in Pharmacology, 14(8): DOI No. 10.3389/fphar.2023.1135898 {ISSN: 1663-9812} Impact Factor= 5.828
  • "Integrons in the Development of Antimicrobial Resistance: Critical Review and Perspectives" Frontiers in Microbiology, 14(8): DOI No. 10.3389/fmicb.2023.1231938 {ISSN: 1664-302X} Impact Factor= 5.289
  • "Elucidation of Interleukin-19 as a therapeutic target for breast cancer by computational analysis and experimental validation" Saudi Journal of Biological Sciences, 30(9): DOI No. 10.1016/j.sjbs.2023.103774 {ISSN: 1319-562X} Impact Factor= 4.465
  • "A network pharmacology-based investigation of brugine reveals its multi-target molecular mechanism against Breast Cancer" Medical Oncology, 40(6): DOI No. 10.1007/s12032-023-02067-w {ISSN: 1559-131X} Impact Factor= 3.4
  • "Mechanistic elucidation of Juglanthraquinone C targeting breast Cancer: A network Pharmacology-based investigation" Saudi Journal of Biological Sciences, 30(7): DOI No. 10.1016/j.sjbs.2023.103705 {ISSN: 1319-562X} Impact Factor= 4.465
  • "A comprehensive analysis of notch signalling genes in breast cancer: Expression pattern and prognostic significance" Advances in Cancer Biology - Metastasis, 7(7): DOI No. 10.1016/j.adcanc.2023.100104 {ISSN: 2667-3940} Impact Factor= 0.845
  • "Physicochemical and Anti-fungal Studies of the Pharmaceutical Co-crystal/Salt of Fluconazole" Molecular Pharmaceutics, 20(7): DOI No. 10.1021/acs.molpharmaceut.3c00 {ISSN: 1543-8392} Impact Factor= 5.678
  • "Immunotherapies against human bacterial and fungal infectious diseases" Frontiers in Medicine, 10(4): DOI No. 10.3389/fmed.2023.1135541 {ISSN: 2296-858X} Impact Factor= 3.985
  • "Effect of quercetin on steroidogenesis and folliculogenesis in ovary of mice with experimentally-induced polycystic ovarian syndrome" Frontiers in Endocrinology, 14(4): DOI No. 10.3389/fendo.2023.1153289 {ISSN: 1664-2392} Impact Factor= 5.286
  • "Role of diacerein on steroidogenesis and folliculogenesis related genes in ovary of letrozole-induced PCOS mice" Chemico Biological Interactions, 377(4): DOI No. 10.1016/j.cbi.2023.110468 {ISSN: 1872-7786} Impact Factor= 5.192
  • "Targeting tumor microenvironment using tumor-infiltrating lymphocytes as therapeutics against tumorigenesis" Immunologic Research, 71(4): DOI No. 10.1007/s12026-023-09376-2 {ISSN: 1559-0755} Impact Factor= 4.487
  • "Chlorogenic Acid Restores Ovarian Functions in Mice with Letrozole-Induced Polycystic Ovarian Syndrome Via Modulation of Adiponectin Receptor" Biomedicines, 11(3): DOI No. 10.3390/biomedicines11030900 {ISSN: 2227-9059} Impact Factor= 4.758
  • "Ginger extract ameliorates endocrine-metabolic disturbances in letrozole-induced PCOS mice model by altering androgen- adiponectin status" Obesity Medicine, 39(5): DOI No. 10.1016/j.obmed.2023.100485 {ISSN: 2451-8476} Impact Factor= 2.456
  • "Pharmaceutical salts of azole anti-fungal drugs: physicochemical behaviour and activity studies" RSC Pharmaceutics, 2024(4): DOI No. https://doi.org/10.1039/d4pm00 {ISSN: 2976-8713} Impact Factor= 5.4
  • "Cytochrome c and Cancer Cell Metabolism: A New Perspective" Advances in Cancer Biology-Metastasis, 13(3): DOI No. https://doi.org/10.1016/j.adca {ISSN: 2667-3940} Impact Factor= 2.0
  • "An update on Cancer stem cell survival pathways involved in chemoresistance in Triple-Negative Breast Cancer" Future Oncology, 21(6): DOI No. https://doi.org/10.1080/147966 {ISSN: 1479-6694} Impact Factor= 4.2
  • "Unravelling the Oncogenic Potential and Prognostic Significance of Microtubule-Associated Protein Tau (MAPT) in Breast Cancer: An In-Silico inhibition of MAPT by Paclitaxel" Advances in Cancer Biology-Metastasis, 13(4): DOI No. https://doi.org/10.1016/j.adca {ISSN: 2667-3940} Impact Factor= 2.0
  • "Chloroquine sensitises hypoxic colorectal cancer cells to ROS-mediated cell death via structural disruption of pyruvate dehydrogenase kinase 1" Free Radical Biology and Medicine, 227(2): DOI No. https://doi.org/10.1016/j.free {ISSN: 1873-4596} Impact Factor= 7.1
  • "Molecular Prediction and Correlation of the Structure and Function of Universal Stress Protein A (UspA) from Salmonella Typhimurium" Biochemical Genetics, 63(2): DOI No. https://doi.org/10.1007/s10528 {ISSN: 1573-4927} Impact Factor= 2.1
  • "Pathway Targeting and Mechanistic Elucidation of Phyto-compounds Relevant in Triple-negative Breast Cancer (TNBC)" The Natural Products Journal, 15(4): DOI No. https://doi.org/10.2174/012210 {ISSN: 2210-3155} Impact Factor= 2.0
  • "Targeting mutant p53: a key player in breast cancer pathogenesis and beyond" Cell Communication and Signaling, 22(10): DOI No. https://doi.org/10.1186/s12964 {ISSN: 1478-811X} Impact Factor= 8.4
  • "Mutant P53 Modulation by Cryptolepine through Cell Cycle Arrest and Apoptosis in Triple Negative Breast Cancer" Biomedicine and Pharmacotherapy, 179(10): DOI No. https://doi.org/10.1016/j.biop {ISSN: 1950-6007} Impact Factor= 7.5
  • "Exploring SALL4 as a significant prognostic marker in breast cancer and its association with progression pathways involved in cancer genesis" Computational Biology and Chemistry, 112(10): DOI No. https://doi.org/10.1016/j.comp {ISSN: 1476-9271} Impact Factor= 3.2
  • "Targeting p53 misfolding conundrum by stabilizing agents and their analogues in breast cancer therapy: a comprehensive computational analysis" Frontiers in Pharmacology, 15(1): DOI No. https://doi.org/10.3389/fphar. {ISSN: 1663-9812} Impact Factor= 5.7
  • "Topical retinoid drug Adapalene: A new frontier in cancer treatment" Results in Chemistry, 10(8): DOI No. https://doi.org/10.1016/j.rech {ISSN: 2211-7156} Impact Factor= 2.8
  • "Pharmaceutical salts of azole anti-fungal drugs: physicochemical behaviour and activity studies" ACS-RSC Pharmaceutics, 20(1): DOI No. 10.1039/D4PM00003J {ISSN: eISSN 2976} Impact Factor= 5.3
  • "Microbiota, Natural Products, and Human Health: Exploring Interactions for Therapeutic Insights Natural products and gut Microbiome in Human Health" Frontiers in Cellular and Infection Microbiology, 14(6): DOI No. https://doi.org/10.3389/fcimb. {ISSN: 2235-2988} Impact Factor= 5.6
  • "Exploring the role of trifarotene against RAR-a: an investigation of expression pattern and clinicopathological significance of RAR-a in breast cancer" Frontiers in Pharmacology, 15(6): DOI No. https://doi.org/10.3389/fphar. {ISSN: 1663-9812} Impact Factor= 6.4
  • "Cryptolepine: A naturally derived alkaloid inhibits breast cancer progression by blocking cell cycle progression and inducing apoptosis" Journal of Clinical Oncology, 42(16): DOI No. https://doi.org/10.1200/JCO.20 {ISSN: 1527-7755} Impact Factor= 42.7
  • "SORBS1 expression as a biomarker for obesity and breast cancer prognosis: Insights from genomic analysis and survival outcomes" Journal of Clinical Oncology, 42(16): DOI No. https://doi.org/10.1200/JCO.20 {ISSN: 1527-7755} Impact Factor= 42.7
  • "Exploring HMMR as a therapeutic frontier in breast cancer treatment, its interaction with various cell cycle genes, and targeting its overexpression through specific inhibitors" Frontiers in Pharmacology, 15(3): DOI No. https://doi.org/10.3389/fphar. {ISSN: 1663-9812} Impact Factor= 6.4
  • "ranscription factors-golden keys to modulate the plant metabolism to develop salinity tolerance" Plant Stress, 11(3): DOI No. https://doi.org/10.1016/j.stre {ISSN: ISSN: 2667} Impact Factor= 7.6
  • "Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology" Heliyon, 10(3): DOI No. 10.1016/j.heliyon.2024.e24670 {ISSN: 2405-8440} Impact Factor= 4.5
  • "Administration of metformin ameliorates endocrine abnormalities associated with mouse model of PCOS by increasing Cyp19a1 expression" Comparative Clinical Pathology, 32(5): DOI No. https://doi.org/10.1007/s00580 {ISSN: 1618-565X} Impact Factor= 2.7

Books Published

  • "Introduction to Costimulation and Costimulatory Molecules". Elsevier Publishers USA. {ISBN: 978-0-12-80-2585-7} pp 44
  • "Concept of Reverse Costimulation and Its Role in Diseases". Elsevier Publishers USA. {ISBN: 978-0-12-80-2585-7} pp 37
  • "Costimulation Immunotherapy in Infectious Diseases". Elsevier Publishers USA. {ISBN: 978-0-12-80-2585-7} pp 45
  • "Costimulation Immunotherapy in Allergies and Asthma". Elsevier Publishers USA. {ISBN: 978-0-12-80-2585-7} pp 47
  • "Costimulation in Lymphomas and Cancers". Elsevier Publishers USA. {ISBN: 978-0-12-80-2585-7} pp 69
  • "T-Cell Costimulation and Its Applications in Diseases". Elsevier Publishers USA. {ISBN: 978-0-12-80-2585-7} pp 38
  • "Role of Natural Herbs in Stroke Prevention and Treatment". Nova Science Biomedical Publishers USA. {ISBN: 978-1-63483-555-8} pp 264
  • "An Introduction to Cerebrovascular Diseases". Nova Science Publishers New York USA. {ISBN: 978-1-63483-555-8} pp 51
  • "Immunobiology of Stroke". Nova Science Publishers New York USA. {ISBN: 978-1-63483-555-8} pp 61
  • "Natural Herbs, Human Brain and Neuroprotection". Nova Science Publishers New York USA. pp 62
  • "Natural Herbs in Stroke prevention and Treatment". Nova Science Publishers New York USA. pp 36
  • "Polyphenols from Natural Herbs in Neuroprotection". Nova Science Publishers New York USA. pp 47
  • "Role of Natural Herbs in Prevention and Treatment of Stroke". Nova Science Publishers New York USA. {ISBN: 978-1-63483-574-9} pp 310
  • "Basics and Fundamentals of Immunology". Nova Science Publishers USA. {ISBN: 978-1-53616-639-2} pp 334
  • "Immunoglobulins, Magic Bullets and Therapeutic Antibodies". Biomedical NOVA Science Publishers Newyork USA. {ISBN: 978-1-53616-903-4} pp 365
  • "Cytokines and their Therapeutic potential". Nova Science Publishers Newyork USA. {ISBN: 978-1-53617-017-7} pp 285
  • "The fundamentals of Hypersensitivities and Allergies". Nova Biomedical Science Publishers New York USA. {ISBN: 978-1-53617-012-2} pp 184
  • "Plant Metabolites in the Treatment of Cancer and cerebrovascular Diseases". OMICS Science International Publishers USA. {ISBN: 978-1-63278-073-7} pp 176
  • "Natural Medicine in Cerebrovascular Diseases". Ariana Publishers New Delhi India. {ISBN: 9789385497940} pp 127
  • "Nanomedicine in Human Health Therapeutics and Drug Delivery/Applications of Nanomaterials in Agriculture, Food Science, and Medicine". IGI Global Publishers. {ISBN: 9781799855644} pp 23
  • "Combination Therapies and their Effectiveness in Breast Cancer Treatment". NOVA Biomedical Science Publishers USA. {ISBN: 978-1-68507-195-0} pp 345
  • "Integrating Immunotherapy with Targeted Therapies and Chemotherapy: A New Paradigm in TNBC Treatment". Intech Open International Publishers UK. {ISBN: 978-1-83969-958-0} pp 46
  • "Role of immunogenetics polymorphisms in infectious diseases". Elsevier Publishers USA. {ISBN: 978-0-323-90053-9} pp 56
  • "Antioxidants (Natural and Synthetic) Screening Assays: An Overview". Bentham Science Publishers. {ISBN: 978-981-4998-88-8} pp 22
  • "Antioxidants in Cancer Prevention and Combination Therapy". Bentham Science Publishers. {ISBN: 978-981-4998-88-8} pp 18
  • "Immuno-onco-metabolism and Therapeutic Resistance". Springer Nature. {ISBN: 978-9811662256} pp 36
  • "Combinational Therapy in Triple Negative Breast Cancer". Elsevier Sciences USA. {ISBN: 9780323961363} pp 368
  • "Human Pathogenic Microbes: Diseases and Concerns". Elsevier Sciences USA. {ISBN: 9780323961271} pp 412
  • "Chapter 1 - Human pathogenic microbes (bacterial and fungal) and associated diseases". Elsevier. {ISBN: 978-0-323-96127-1} pp 30
  • "Chapter 2 - Evolution of antimicrobial drug resistance in human pathogenic bacteria". Elsevier. {ISBN: 978-0-323-96127-1} pp 22
  • "Chapter 3 - Evolution of antimicrobial drug resistance in human pathogenic fungi". Elsevier. {ISBN: 978-0-323-96127-1} pp 18
  • "Chapter 4 - Combating human bacterial infections: need for new antibacterial drugs and therapeutics". Elsevier. {ISBN: 978-0-323-96127-1} pp 31
  • "Chapter 5 - Combating human fungal infections: need for new antifungal drugs and therapies". Elsevier. {ISBN: 978-0-323-96127-1} pp 25
  • "Chapter 6 - Significance of immunotherapy for human bacterial diseases and antibacterial drug discovery". Elsevier. {ISBN: 978-0-323-96127-1} pp 32
  • "Chapter 7 - Significance of immunotherapy for human fungal diseases and antifungal drug discovery". Elsevier. {ISBN: 978-0-323-96127-1} pp 23
  • "Chapter 8 - Combinatorial approach to combat drug resistance in human pathogenic bacteria". Elsevier. {ISBN: 978-0-323-96127-1} pp 20
  • "Chapter 9 - Combinatorial approach to combat drug resistance in human pathogenic fungi". Elsevier. {ISBN: 978-0-323-96127-1} pp 16
  • "Chapter 10 - Recent trends in the development of bacterial and fungal vaccines". Elsevier. {ISBN: 978-0-323-96127-1} pp 27
  • "Human pathogenic microbes: diseases and concerns". Elsevier USA. {ISBN: 9780323961271} pp 432
  • "Combinational Therapy in Triple Negative Breast Cancer". Elsevier USA. {ISBN: 9780323961363} pp 386
  • "Role of tumor microenvironment in breast cancer and targeted Therapies". Elsevier USA. {ISBN: 9780443186967} pp 297
  • "Therapeutic potential of Cell Cycle Kinases in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 373
  • "Proteomics: A groundbreaking development in cancer biology". Springer Nature. {ISBN: 978-0-323-95072-5} pp 23
  • "Proteomics: Application of next-generation proteomics in cancer research". Springer Nature. {ISBN: 978-0-323-95072-5} pp 24
  • "Introduction to Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 22
  • "Current Treatment Approaches to Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 29
  • "Introduction to Cell Cycle and Its Regulators". Springer Nature. {ISBN: 978-981-19-8911-7} pp 30
  • "Cell Cycle and Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 19
  • "Cell Cycle Dysregulation in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 29
  • "Breast Tumor Microenvironment and CDKs". Springer Nature. {ISBN: 978-981-19-8911-7} pp 26
  • "CDK Dysregulation in Breast Cancer: A Bioinformatics Analysis". Springer Nature. {ISBN: 978-981-19-8911-7} pp 20
  • "CDK1 Dysregulation in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 16
  • "Cdk4/Cdk6 Dysregulation in Estrogen-Positive Receptor Breast Cancers". Springer Nature. {ISBN: 978-981-19-8911-7} pp 22
  • "Therapeutic Implications of CDKs in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 20
  • "Novel CDK Inhibitors in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 16
  • "Targeting CDKs with Other Chemotherapeutic Drugs: A Combinatorial Approach". Springer Nature. {ISBN: 978-981-19-8911-7} pp 21
  • "CDKs in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 21
  • "CDk Inhibitor for Treatment of Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 21
  • "Response of Therapy in Cell-Cycle Regulatory Genes in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 19
  • "Different Cyclins and Their Significance in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 19
  • "Cytokine and Chemokine Networks in Cancer". Springer Nature. {ISBN: 978-981-99-4657-0} pp 440
  • "Therapeutic potential of Cell Cycle Kinases in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 373
  • "Novel Approaches in Metronomic Chemotherapy for Breast Cancer Treatment". Taylor and Francis CRC Press. {ISBN: 9781032620459} pp 208
  • "Introduction to Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 22
  • "Current Treatment Approaches to Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 28
  • "Introduction to Cell Cycle and Its Regulators". Springer Nature. {ISBN: 978-981-19-8911-7} pp 30
  • "Cell Cycle and Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 18
  • "Cell Cycle Dysregulation in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 29
  • "Molecular Subtypes of Breast Cancer and CDk Dysregulation". Springer Nature. {ISBN: 978-981-19-8911-7} pp 16
  • "Breast Tumor Microenvironment and CDKs". Springer Nature. {ISBN: 978-981-19-8911-7} pp 25
  • "CDK Dysregulation in Breast Cancer: A Bioinformatics Analysis". Springer Nature. {ISBN: 978-981-19-8911-7} pp 20
  • "CDK1 Dysregulation in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 16
  • "Cdk4/Cdk6 Dysregulation in Estrogen-Positive Receptor Breast Cancers". Springer Nature. {ISBN: 978-981-19-8911-7} pp 21
  • "Therapeutic Implications of CDKs in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 20
  • "Novel CDK Inhibitors in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 15
  • "Targeting CDKs with Other Chemotherapeutic Drugs: A Combinatorial Approach". Springer Nature. {ISBN: 978-981-19-8911-7} pp 21
  • "CDKs in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 21
  • "CDk Inhibitor for Treatment of Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 20
  • "Response of Therapy in Cell-Cycle Regulatory Genes in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 19
  • "Different Cyclins and Their Significance in Breast Cancer". Springer Nature. {ISBN: 978-981-19-8911-7} pp 18
  • "Introduction to Cytokine and Chemokine Networks". Springer Nature. {ISBN: 978-981-99-4657-0} pp 31
  • "Cytokines and Chemokines in Tumor Growth and Progression". Springer Nature. {ISBN: 978-981-99-4657-0} pp 44
  • "Chemokine and Cytokine Network in Angiogenesis". Springer Nature. {ISBN: 978-981-99-4657-0} pp 36
  • "Implications of Chemokine Heterogenicity in Cancer Metastasis". Springer Nature. {ISBN: 978-981-99-4657-0} pp 21
  • "The Role of Interleukin (IL)-6/IL-6 Receptor Axis in Cancer". Springer Nature. {ISBN: 978-981-99-4657-0} pp 34
  • "The Interleukin-8 Pathway in Cancer". Springer Nature. {ISBN: 978-981-99-4657-0} pp 26
  • "CXCL12–CXCR4 Axis in Cancer Metastasis". Springer Nature. {ISBN: 978-981-99-4657-0} pp 27
  • "CCL5/CCR5 Axis in Cancer". Springer Nature. {ISBN: 978-981-99-4657-0} pp 22
  • "CCL2–CCR2 Signaling Axis in Cancer". Springer Nature. {ISBN: 978-981-99-4657-0} pp 30
  • "CXCL9, CXCL10, CXCL11/CXCR3 Axis and Immune Activation". Springer Nature. {ISBN: 978-981-99-4657-0} pp 19
  • "Role of the CXCL8–CXCR1/2 Axis in Cancer and Inflammatory Diseases". Springer Nature. {ISBN: 978-981-99-4657-0} pp 39
  • "Chemokine and Cytokine Networks in Tumor Microenvironment". Springer Nature. {ISBN: 978-981-99-4657-0} pp 22
  • "Prognostic and Diagnostic Significance of Chemokines and Cytokines in Cancer". Springer Nature. {ISBN: 978-981-99-4657-0} pp 32
  • "Therapeutic Implications of Cytokines and Chemokines Network in Cancer". Springer Nature. {ISBN: 978-981-99-4657-0} pp 30
  • "Chemokines in Cancer Therapy". Springer Nature. {ISBN: 978-981-99-4657-0} pp 26
  • "Introduction to Metronomic Chemotherapy". Taylor and Francis CRC Press. {ISBN: 9781032620459} pp 15
  • "Metronomic Chemotherapy: A Multitargeted Therapy". Taylor and Francis CRC Press. {ISBN: 9781032620459} pp 13
  • "Conventional Chemotherapy vs. Metronomic Chemotherapy". Taylor and Francis CRC Press. {ISBN: 9781032620459} pp 17
  • "The Antiangiogenic Basis of Metronomic Chemotherapy". Taylor and Francis CRC Press. {ISBN: 9781032620459} pp 16
  • "Imaging Techniques, Biomarkers, and Methods for Metronomic Chemotherapy". Taylor and Francis CRC Press. {ISBN: 9781032620459} pp 15
  • "Metronomic Chemotherapy in Breast Cancer". Taylor and Francis CRC Press. {ISBN: 9781032620459} pp 16
  • "Metronomic Chemotherapy in Combination with an Anti-Cancer Vaccine". Taylor and Francis CRC Press. {ISBN: 9781032620459} pp 13
  • "Metronomics: Toward Personalized Chemotherapy". Taylor and Francis CRC Press. {ISBN: 9781032620459} pp 22
  • "Metronomic Chemotherapy for Metastatic Breast Cancer". Taylor and Francis CRC Press. {ISBN: 9781032620459} pp 11
  • "Recent Advances, Challenges, and the Future of Metronomic Chemotherapy". Taylor and Francis CRC Press. {ISBN: 9781032620459} pp 11
  • "Targeted Therapies in Combination with Metronomic Chemotherapy". Taylor and Francis CRC Press. {ISBN: 9781032620459} pp 13
  • "Recent Advances in Metronomic Chemotherapy: Nanotechnology-Based Low-Dose Chemotherapy in Breast Cancer". Taylor and Francis CRC Press. {ISBN: 9781032620459} pp 18
  • "Novel Approaches in Metronomic Chemotherapy for Breast Cancer Treatment". Taylor and Francis CRC-Press UK. {ISBN: 9781032620459} pp 208
  • "p53 in Breast Cancer Molecular Mechanisms, Clinical Implications, and Therapeutic Targets". Taylor and Francis CRC-Press UK. {ISBN: 9781032859828} pp 329
  • "Role of the Tumor Microenvironment in Cancer Immunotherapy". Springer-Nature Singapore. {ISBN: 978-981-97-7021-2} pp 26
  • "Antifungal Therapies and Drug Resistance". Taylor and Francis CRC-Press UK. {ISBN: 9781032642864} pp 16

Research Projects Details:

Title of the ProjectFunding AgencyDatedAmount (in Rs.)
TNF receptor modulation and its impact on the cellular survival by natural herbs in oxygen glucose deprivation model of strokeSheikh Abdullah Bin Tuwaijri Chair for Applied Research in Stroke (SATCAS) Majmaah University KSA01-01-2015180,000.00
Neuroprotective effect of Elsholtzia densa and Artemisia amygdalina in cellular survival after Cerebral Ischemia in oxidative/inflammatory in vitro model of StrokeBHSR Centre Majmaah University25-03-20151,000,000.00
Elucidation of Molecular Mechanisms of Drug and Multidrug Resistance of MTB in Kashmir ValleySERB-DST GOI10-06-20191,850,000.00
Elucidation of Molecular Basis of Drug and Multidrug Tuberculosis Resistance of Mycobacterium tuberculosis in Kashmir ValleyScience and Engineering Research Board, Department of Science and Technology (SERB-DST) Govt of India11-09-20201,850,000.00
Targeting drug resistance cancer stem cells by combinational delivery of Quercetin/ Zerumbone in breast cancerJammu Kashmir Science Technology and Innovation Council Govt (JKDST&IC)27-10-20211,000,000.00
Elucidation of Molecular Basis of Drug and Multi-Drug Tuberculosis Resistance of mycobacterium tuberculosis in Kashmir ValleySCience and Engineering Research Board, Department of Science and Technology Govt of India (SERB-DST)10-06-20191,860,000.00
Targeting Drug Resistant cancer Stem Cells by Combinational delivery of paclitaxel and Quercetin/Zarambone in Breast cancerJKST&IC DST Govt of J&K27-10-20231,000,000.00
Targeting drug resistant cancer stem cells by combinational delivery of Paclitaxel and Quercetin/Zerumbone in breast cancerJKST&IC Department of Science and Technology Govt of J&K (UT)27-10-20241,000,000.00

Research Scholars:

NameCourseStatusNature
Basharat Ahmad BhatPh.D Awarded Whole Time
Umar MehrajPh.D Awarded Whole Time
Bashir Ahmad SheikhPh.D Awarded Whole Time
Miss Mehak MajeedPh.D Awarded Whole Time

Teaching:

DepartmentSubjectCourse TaughtSemester
Bio-ResourcesM. Sc BioresourcesAnimal Resources1
Bio-ResourcesM. Sc BioresourcesBasic and Applied Immunology1
Bio-ResourcesM. Sc BioresourcesLab Practical Work based on I, II and III1
Bio-ResourcesM. Sc BioresourcesIndustrial Immunology1
Bio-ResourcesM. Sc BioresourcesAnimal Resource Regeneration2
Bio-ResourcesM. Sc BioresourcesInheritance Biology2
Bio-ResourcesM. Sc BioresourcesInfectius Diseases and Human Health2
Bio-ResourcesM. Sc BioresourcesBiostatistics and Biotechniques3
Bio-ResourcesM. Sc BioresourcesCellular and Molecular Immunology3
Bio-ResourcesM. Sc BioresourcesLab Practical Work based on I, II and III3
Bio-ResourcesM. Sc BioresourcesInfectious Diseases and Live Stock Health3
Bio-ResourcesM. Sc BioresourcesAnimal Cell and Tisuue Technology4
Bio-ResourcesM. Sc BioresourcesMicrobial Technology4
Bio-ResourcesM. Sc BioresourcesProject Work4
Bio-ResourcesM. Sc BioresourcesLab Practical Work based on I, II and III4
Bio-ResourcesM. Sc BioresourcesBioindustries4